idea-009 · desirability deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: the user. Here that is an adult with below-knee lymphedema in the maintenance phase of therapy who cannot pull on a flat-knit compression garment — and, standing behind them, the clinician who directs the therapy, the fitter or supplier who hands over the product, and the family member who may end up doing the strapping.
How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points at a numbered line of the ## Claims list in knowledge-base/candidates/idea-009.md (numbered by position) and carries the tag that line carries there, copied and never adjusted here. [no claim] would mean nothing in the file speaks to a condition; after this build's write-back, none of the conditions below is in that state — which is not good news, because most of them rest on unconfirmed or unverified. See docs/deck-spec.md.
One thing to hold while reading: the rubric scores nothing about whether a user wants this, and the candidate's own Gate Check says so ("the nine rubric factors do not score whether a user wants the thing"). Every verified claim in the file is about regulation text, code descriptors, payment rules or billed volume. Not one of them is about what a patient, clinician or caregiver does. Expect this deck to have nothing verified behind it, and read that as information about the pipeline as much as about the idea.
Would have to be true: Adults in the maintenance phase of below-knee lymphedema would have to be failing or abandoning their prescribed flat-knit garments because they cannot put them on, and would have to be failing with a garment donning aid as well — otherwise the moment this product is built for is either rare or already solved.
Where it stands: That garments are failed or abandoned for donning reasons in this population is on record as an assumption only claim 26unconfirmed. The literature leads the file carries on donning difficulty are from other populations or products — an upper-limb cohort in Turkey claim 49unconfirmed and hosiery wearers in the Netherlands claim 50unconfirmed — and cannot tag this line. Whether a donning aid already meets the need was never asked before this build; it is now on record claim 67unverified. What is verified is adjacent, not supporting: below-knee stocking codes carrying explicit mmHg (millimetres of mercury) ranges exist as the garment alternative claim 9verified, and wraps under A6583 (a HCPCS code for a supply) were billed for 24,631 Medicare fee-for-service beneficiaries in 2024 claim 15verified — which shows wraps already reach users, and says nothing about why those users are in a wrap rather than a garment.
What would settle it: Interviews or a chart review with certified lymphedema therapists and fitters covering maintenance-phase below-knee patients: how many are in a flat-knit garment, how many have failed one, and whether donning was the reason. A separate short protocol puts patients who report they cannot self-don a garment in front of the common donning aids. The adoption connector returns unverifiable by design on both; this is commissioned primary research, a human act.
If it's false: If donning failure is rare, or a donning aid already fixes it, the indicated population the intended_use: is written around ("patients who are unable to self-don a flat-knit compression garment") is small or already served, and every later slide in this deck — and the viability deck's Slide 3 share operand — is sized to a need that isn't there.
Would have to be true: A patient who cannot self-don a flat-knit garment would have to be able to wrap, strap and align every tension indicator on their own lower leg, unaided, at each donning — and keep doing it to target tension for months, not only at a supervised first fitting.
Where it stands: The file names this as the desirability crux and records zero evidence on either side: that the indicated population can self-apply a multi-strap wrap and read its indicators, including patients with hand arthritis, obesity or limited hip flexion claim 23unconfirmed; that they will re-apply to target tension over months of use claim 27unconfirmed; and that the indicator makes their achieved tension more consistent than a strap without one claim 68unverified. Two literature leads sit near it and do not reach it: 95.3% of 86 chronic-leg-oedema patients could don a different manufacturer's inelastic adjustable system independently or with a little help from relatives claim 47unconfirmed, and adjustable wraps went on faster than multilayer bandaging in 24 patients — in the intensive phase, not maintenance claim 46unconfirmed.
What would settle it: A handful of supervised donning sessions in the indicated population — people who have failed a flat-knit garment — recording whether each strap's indicator is aligned unaided, then the same patients re-assessed after unsupervised home use. The file itself names this as "testable cheaply". Only a human with patient access can run it.
If it's false: The product's premise inverts: an indication defined by an inability to self-apply one compression product meets a second self-applied product that also fails. The fallback is caregiver application (Slide 3), which changes who the user is. The § 880.9 lay-use question on the feasibility deck's Slide 3 becomes moot in the worst way.
Would have to be true: A licensed clinician would have to direct a self-applied wrap in place of a flat-knit garment or repeat bandaging, a prescriber would have to document arterial status before first use, a fitter or DMEPOS (durable medical equipment, prosthetics, orthotics and supplies) supplier would have to stock and hand over a fifth brand, and — where the patient cannot strap it unaided — a household caregiver would have to be there to do it to tension at every donning.
Where it stands: Every link in the chain is on record and none is evidenced. Clinician acceptance is written into the intended_use: itself ("under the direction of a licensed clinician") and is an assumption claim 25unconfirmed. Arterial-status documentation before first use claim 28unconfirmed sits under a clinical-risk claim that names use over undiagnosed peripheral arterial disease as the material hazard claim 21unconfirmed. Fitter and supplier willingness to stock a new brand is the viability deck's question (its Slide 6) and rests there claim 24unconfirmed. Caregiver availability claim 30unconfirmed. The file's hosiery study lead reports donning difficulty producing dependency on informal or home care, in the Netherlands claim 50unconfirmed.
What would settle it: Structured interviews with lymphedema-certified therapists and prescribers (would they direct it, and would they order an ankle-brachial index first), with DMEPOS suppliers who dispense A6583 (would they stock it), and with patients and caregivers in the indicated population (who straps the leg today). The adoption connector is unverifiable for all four by design; a synthetic stakeholder opinion would be a fabricated claim.
If it's false: A refusal anywhere in this chain stops the product reaching the leg, whatever Slide 2 shows. A clinician who will not direct it closes the indication; a prescriber who will not screen arterial status leaves the file's named harm pathway open, which is a feasibility and labelling problem (feasibility deck, Slide 6).
Would have to be true: The Medicare beneficiary's share of each wrap — the Part B deductible, then 20% coinsurance on the allowable — would have to be low enough that prescribed patients do not decline or abandon the wrap over it, and the daily time and effort of strapping would have to be tolerable in a population defined by donning difficulty.
Where it stands: The money operand is verified: Medicare pays 80% of the lesser of the actual charge or the fee-schedule amount, the deductible applies, and the July 2026 non-rural allowable for A6583 is $160.13 per wrap claim 11verified. The file records the beneficiary's 20% as about $32 per wrap on a line whose behavioural half — that this sum does not drive abandonment — is untested claim 53unconfirmed. How many wraps a patient needs in a period, and so what they pay per year, turns on quantity limits the file has not read claim 45unconfirmed and on coverage breadth by diagnosis claim 12unconfirmed. Paying out of pocket above the coinsurance is the viability deck's question (its Slide 1) claim 55unconfirmed. The daily time cost is not measured in this population at all; the nearest lead is intensive-phase application time claim 46unconfirmed.
What would settle it: Supplier dispensing records on prescribed-but-not-collected A6583 orders (a supplier would have to share them), plus patient interviews on the coinsurance and on daily strapping time. The DME MAC (durable medical equipment Medicare administrative contractor) lymphedema compression policy article, read directly, settles the quantity half.
If it's false: If the coinsurance alone drives abandonment, the verified payment rule funds a product patients leave at the counter; if strapping takes longer than the garment it replaces, Slide 2's behaviour change does not stick.
Would have to be true: Patients would have to perceive a limb-volume or symptom change they attribute to the wrap within the first weeks of maintenance use — the evidence a user acts on, which is not the evidence the exempt regulatory route asks for (it asks for none).
Where it stands: On record as an assumption only claim 29unconfirmed. The file's one continuation signal — 83.3% of 24 trial participants saying they would keep using adjustable wraps — is from the intensive phase, not maintenance claim 46unconfirmed. Whether gradient compression is established maintenance therapy at all is itself unverified here claim 21unconfirmed.
What would settle it: Limb-volume or circumference measurements, plus a symptom question, in the first weeks of home use by the same patients recruited for Slide 2's donning sessions. A human-run observation, not a connector call.
If it's false: A maintenance therapy whose benefit is felt as "nothing got worse" gives the user no week-one reason to keep strapping, and Slide 2's months-long adherence condition claim 27unconfirmed loses its support.
Would have to be true: In the first handful of real users — people who have failed a flat-knit garment — every strap indicator would have to be aligned unaided at a supervised donning, and still aligned at a later unsupervised one; an unaligned indicator, or a caregiver's hands on the straps, is the observation that falsifies Slide 2.
Where it stands: Nothing has been observed. The conditions this test reads are all assumptions claim 23unconfirmed, claim 27unconfirmed, claim 68unverified, and the nearest published donning result is another maker's product in a broader oedema population claim 47unconfirmed.
What would settle it: Recruit through a lymphedema therapy clinic; photograph strap indicators at each donning; repeat the same donnings with the indicators masked, which is what separates the indicator's contribution claim 68unverified from the wrap's. A human act with patient access; no connector reaches it.
If it's false: The desirability case collapses to "an adjustable-strap wrap", a category already billed 80,433 times to Medicare fee-for-service in 2024 claim 15verified — so the wrap reaches users today without this product's differentiator.
Every condition above with nothing verified behind it. On this deck that is all six. The verified claims cited above (the garment codes, the payment rule and allowable, the 2024 billed volume) are context around the conditions, never support for them.
Two of these are this build's own write-back, now on the Verifier's list as unverified (claims 67 and 68). The rest were already on record as unconfirmed, and the file states plainly why most will stay that way: adoption is unverifiable by design, and only commissioned primary research moves them.
If only one thing from this chair could be checked: whether a patient who cannot self-don a flat-knit garment can strap this wrap to its indicated tension, unaided, and does so more consistently because of the indicator claim 23unconfirmed, claim 68unverified.
This one rather than the others because it is two questions answered by one session: the first half is the premise the indication is built on (the file calls it "the sharpest thing in this file"), and the second half is the only thing that separates this product from the adjustable-strap wraps Medicare already paid for in 2024. Every other condition on this deck — clinician acceptance, cost tolerance, week-one belief — is about a user who has already got the wrap on.
Naming it is not a recommendation, a gate, or a kill. It is the answer to "check what first."
_shared/plain-language.md